Posts

CTP-543 for Alopecia Areata

CTP-543 for Alopecia Areata

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA2 in the second half of 2022. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve as the basis for submitting a New Drug Application to the U.S. Food and Drug Administration (FDA) in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

“We expect the CTP-543 THRIVE-AA clinical program to provide the pivotal data needed to support our registration,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “The continued support of the alopecia areata community has been essential in progressing our program, and the initiation of this second Phase 3 trial brings us another step closer to seeking FDA-approval. We are hopeful that CTP-543 will be one of the first FDA-approved treatments for alopecia areata and will offer an important therapeutic option for this challenging autoimmune disease.”

“Alopecia areata can bring disruption and burden to daily life. But with the progress of clinical trials, there’s hope for patients,” said Thea Chassin, the Founder and Chief Executive Officer of Bald Girls Do Lunch Inc., an alopecia areata advocacy, education and support nonprofit. “We’re grateful for Concert’s research on behalf of the alopecia areata community. We applaud Concert’s goal to develop a potential new medication.”

About the THRIVE-AA2 Study

THRIVE-AA2 (NCT04797650) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT). Key aspects of THRIVE-AA2 include:

  • Patient characteristics: adults age 18-65 years with ≥ 50% hair loss are eligible for the study;
  • Expected enrollment size: approximately 440 patients;
  • Dosing: 8 mg or 12 mg of CTP-543 or placebo twice-daily for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤ 20 at Week 24.

For more information about the THRIVE-AA1 and THRIVE-AA2 studies, please visit www.clinicaltrials.gov.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 1 million Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Source

Recent Posts

CTP-543 for Alopecia Areata

CTP-543 for Alopecia Areata

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA2 in the second half of 2022. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve as the basis for submitting a New Drug Application to the U.S. Food and Drug Administration (FDA) in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

“We expect the CTP-543 THRIVE-AA clinical program to provide the pivotal data needed to support our registration,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “The continued support of the alopecia areata community has been essential in progressing our program, and the initiation of this second Phase 3 trial brings us another step closer to seeking FDA-approval. We are hopeful that CTP-543 will be one of the first FDA-approved treatments for alopecia areata and will offer an important therapeutic option for this challenging autoimmune disease.”

“Alopecia areata can bring disruption and burden to daily life. But with the progress of clinical trials, there’s hope for patients,” said Thea Chassin, the Founder and Chief Executive Officer of Bald Girls Do Lunch Inc., an alopecia areata advocacy, education and support nonprofit. “We’re grateful for Concert’s research on behalf of the alopecia areata community. We applaud Concert’s goal to develop a potential new medication.”

About the THRIVE-AA2 Study

THRIVE-AA2 (NCT04797650) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT). Key aspects of THRIVE-AA2 include:

  • Patient characteristics: adults age 18-65 years with ≥ 50% hair loss are eligible for the study;
  • Expected enrollment size: approximately 440 patients;
  • Dosing: 8 mg or 12 mg of CTP-543 or placebo twice-daily for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤ 20 at Week 24.

For more information about the THRIVE-AA1 and THRIVE-AA2 studies, please visit www.clinicaltrials.gov.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 1 million Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment Market Research Report 2021-2027

The research team projects that the Alopecia Treatment market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this alopecia report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Teva Pharmaceutical Industries

Merck

Johnson&Johnson

Reddy`s Laboratories

Cipla

Cellmid

Himalaya Drug

Taisho Pharmaceutical Holdings

By Type

Topical Drugs

Oral Drugs

Injectable

Hair Transplant Services

Other

By Application

Hospitals

Dermatology And Trichology Clinics

Home Care Settings

Other

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

Russia

Spain

Netherlands

Switzerland

Poland

South Asia

India

Pakistan

Bangladesh

South East Asia

Indonesia

Thailand

Singapore

Malaysia

Philippines

Vietnam

Myanmar

Middle East

Turkey

Saudi Arabia

Iran

United Arab Emirates

Israel

Iraq

Qatar

Kuwait

Oman

Africa

Nigeria

South Africa

Egypt

Algeria

Morocoo

Oceania

Australia

New Zealand

South America

Brazil

Argentina

Colombia

Chile

Venezuela

Peru

Puerto Rico

Ecuador

Rest of the World

Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, By Type, By Application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Alopecia Treatment 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend By Types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further, the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Alopecia Treatment Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis By Application Type: Based on the Alopecia Treatment Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

Global Alopecia Treatment Market Research Report 2021-2027

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

The Alopecia Treatment market is expected to grow in the future due to a rising R&D activity to improve treatment options and accelerated regulatory approvals.

There are five major kinds of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium.

The rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Growth Drivers

  • Surge in Geriatric Population
  • Rise in Prevalence of Alopecia Conditions such as Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others
  • Increase in Prevalence of Chemotherapy-Induced Alopecia

Market Trends

  • Technological Advancements and the Development of Novel Therapeutic Drugs

Roadblocks

  • Lack of Reimbursement Policies
  • High Cost of Medications

Opportunities

  • Surge in Patient Awareness Regarding the Alopecia Totalis Disorder
  • Large Presence of Pharmaceutical Companies

Challenges

  • Side Effects, Reactions, and Allergies Caused by Alopecia Treatments

Competitive Landscape:

The global Alopecia Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.

Some of the key players profiled in the report are Johnson & JohnsonServices, Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Cipla Inc. (India), Lexington International LLC (United States), Merck & Co., Inc. (United States), Vita-Cos-Med Klett-Loch GmbH (Germany), Cirrus Hair Centers (United States), Transitions Hair Pty Ltd. (United States), Capillus (United States) and Follica, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Alopecia Treatment market by 2025.

Considering Market by Drug, the sub-segment i.e. Minoxidil will boost the Alopecia Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Prescriptions will boost the Alopecia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Alopecia Treatment market.

Latest Market Insights:

In Mar 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body.

In June 2020, Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019., and In Oct 2020, Histogen Inc. announced the completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability, and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

Global Alopecia Treatment Market

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia (Hair Loss)Treatment Market Analysis by Region Analysis and Business Development, By 2026

Global  Alopecia (Hair Loss)Treatment market Size study report with COVID-19 effect is considered to be an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with the overall size of the  Alopecia (Hair Loss)Treatment industry, estimated from 2020 to 2026.

The research report also provides a detailed overview of leading industry initiatives, potential market share and business-oriented planning, etc.

The study discusses favourable factors related to current industry conditions, levels of growth of the  Alopecia (Hair Loss)Treatment industry, demands, differentiable business-oriented approaches used by the manufacturers of the  Alopecia (Hair Loss)Treatment industry in brief about distinct tactics and futuristic prospects.

The research report on  Alopecia (Hair Loss)Treatment market provides a comparative study of the historical data with the changing market scenario to reveal the future roadmap of the industry. It offers detailed insights pertaining to the growth markers, challenges and opportunities residing in this industry vertical.

A magnified view of the regional landscape and competitive terrain of this business sphere is also encompassed in the document. In addition, the report reevaluates the market behaviour considering the impact of COVID-19 on the business landscape.

Alopecia (Hair Loss)Treatment  market rundown:

As per the report, North America, Asia-Pacific, Europe, Latin America, Middle East & Africa and Rest of MEA are the key regional contributors of the  Alopecia (Hair Loss)Treatment market.
Information underpinning the market share accounted by each regional market along with their consumption graph and growth rate over the forecast period are included in the report.
Growth opportunities with respect to several economic indicators are listed for providing actionable intelligence to industry partakers.

Competitive outlook of the  Alopecia (Hair Loss)Treatment  market:

Company profiles, inclusive of Cipla, Dr Reddya??s Laboratories,    Regaine,    Merck,    Ranbaxy Laboratories,    Vitabiotics,    Nanogen,    Alpecin and    Johnson and Johnson are listed in the report.
A systematic representation of the product offerings of top contenders, together with their specifications and top applications is given.

An overview of regional terrain:

The manufacturing base of leading players, their operational regions and market share are elucidated.

Pricing models followed by each company and their returns are also recorded.

Updates regarding market concentration rate, key development trends, mergers & acquisitions, and new entrants are documented as well.

Other important takeaways from the  Alopecia (Hair Loss)Treatment  market report:

The product range of the  Alopecia (Hair Loss)Treatment market comprises Vitamins and Supplements,    Shampoos and Conditioners and    Others.
Consumption share, market share, sales price, and remuneration accrued by each product type is encompassed in the report.
The application scope of the various products is categorized into Men,    Women and    Children.
Predictions regarding the consumption value & volume and industry share held by each application are validated.
A comprehensive study of the industry supply chain emphasizing on the distribution channels, producers, distributors, and downstream buyers is furnished in the report.

The report answers important questions that companies may have when operating in the global  Alopecia (Hair Loss)Treatment market. Some of the questions are given below:

What will be the size of the global  Alopecia (Hair Loss)Treatment market in 2026?

What is the current CAGR of the global  Alopecia (Hair Loss)Treatment market?

Which product is expected to show the highest market growth?

Which are the top players currently operating in the global  Alopecia (Hair Loss)Treatment market?

Which application is projected to gain a lion’s share of the global  Alopecia (Hair Loss)Treatment market?

Will there be any changes in market competition during the forecast period?

Which region is foretold to create the most number of opportunities in the global  Alopecia (Hair Loss)Treatment market?

Alopecia (Hair Loss)Treatment Market Analysis by Region Analysis and Business Development, By 2026

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata, their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an autoimmune hair loss on the scalp or on the body and commonly it shows a form of solitary and multiple patches of alopecia.

Market Drivers:

  • The rising geriatric population along with high demand for surgical hair transplant will boost the market
  • Changing lifestyle along with increase in stress level among working-class population can fuel the growth of the market

Market Restraints:

  • High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
  • Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

  • By Disease Type
    • Androgenic Alopecia
    • Alopecia Areata
    • Ciatricial Alopecia
    • Traction Alopecia
    • Alopecia Totalis
  • By Drug Type
    • Minoxidil
    • Finasteride
    • Cyclosporine
    • Others
  • By Gender
    • Male
    • Female
  • By Route of Administration
  • Oral
    • Topical
    • Injectable
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Online Pharmacies
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific
    • Middle East and Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Key Developments in the Market:

  • In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
  • In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
  • In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.

Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment Market Size Share Forecast 2025

Alopecia also called as hair loss or baldness is a very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.

Market Dynamics

Product launches, approvals, and a robust pipeline of novel products is expected to be the major driver of the growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly-owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market.

In May 2018, Histogen, Inc., received the approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in the near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in the market.

For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in the Peoples Republic of China. Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of the market.

According to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is a most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.

Key features of the study:

• This report provides in-depth analysis of alopecia treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

• It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

• It profiles leading players in the global alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

• Key companies covered as a part of this study include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Daiichi Sankyo, Inc., Cipla Limited, and others.

• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

• The global alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the alopecia treatment market

Detailed Segmentation:

• Global Alopecia Treatment Market, By Disease Type :

o Androgenic Alopecia
o Alopecia Areata
o Ciatricial Alopecia
o Traction Alopecia
o Alopecia Totalis

• Global Alopecia Treatment Market, By Drug Type:

o Vasodilators
o Minoxidil
o 5-Alpha Reductase Inhibitors
o Finasteride
o Corticosteroids
o Immunosuppressants
o Cyclosporine
o Others
o Others

• Global Alopecia Treatment Market, By Gender:

o Male
o Female

• Global Alopecia Treatment Market, By Route of Administration:

o Oral
o Topical
o Injectable

• Global Alopecia treatment market, By Distribution Channel:

o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

• Global Alopecia treatment market, By Geography:

Global Alopecia Treatment Market Size Share Forecast 2025

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic diseases like arthritis, cancer, hypertension, depression also lead to hair loss, especially among the middle-aged population.

According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.

Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future.

Concert Pharmaceuticals Inc. received fast track designation from the United States Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Key Market Trends

Female is Expected to Hold Largest Share Over the forecast period

About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it’s less socially acceptable for them.

Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman’s emotional well-being and quality of life.

Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing a hormonal imbalance that leads to androgenetic alopecia.

North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market

North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments.

According to the United States National Library of Medicine, Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.
Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.

Competitive Landscape

Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc.

The development of advanced products for better outcomes and rigorous marketing is one of the competitive strategies adopted by the market players. In 2018, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from the FDA. Furthermore, in 2017, Perrigo Company PLC. Launched over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Source

Previous Posts

Alopecia Treatment Market 2019

Alopecia Treatment Market

Global Alopecia Treatment Market Professional Survey 2019 by Manufacturers, Regions, Countries, Types and Applications, Forecast to 2024

The Alopecia Treatment market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for Alopecia Treatment.

Global Alopecia Treatment industry market professional research 2014-2024, is a report which provides the details about industry overview, industry chain, market size (sales, revenue, growth rate), gross margin, major manufacturers, development trends and forecast.

Key players in the global Alopecia Treatment market include:

Teva Pharmaceutical Industries
Merck
Johnson&Johnson
Reddy’s Laboratories
Cipla
Cellmid
Himalaya Drug
Taisho Pharmaceutical Holdings

Market segmentation, by product types:

Topical Drugs
Oral Drugs
Injectable
Hair Transplant Services
Other

Market segmentation, by applications:

Hospitals
Dermatology And Trichology Clinics
Home Care Settings
Other

Market segmentation, by regions:

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Market segmentation, by countries:

United States
Canada
Germany
France
UK
Italy
Russia
Spain
China
Japan
Korea
India
Australia
New Zealand
Southeast Asia
Middle East
Africa
Mexico
Brazil
C. America
Chile
Peru
Colombia

The report can answer the following questions:

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Alopecia Treatment industry.

2. Global major manufacturers’ operating situation (sales, revenue, growth rate and gross margin) of Alopecia Treatment industry.

3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Alopecia Treatment industry.

4. Different types and applications of Alopecia Treatment industry, market share of each type and application by revenue.

5. Global market size (sales, revenue) forecast by regions and countries from 2019 to2024 of Alopecia Treatment industry.

6. Upstream raw materials and manufacturing equipment, industry chain analysis of Alopecia Treatment industry.

7. SWOT analysis of Alopecia Treatment industry.

8. New Project Investment Feasibility Analysis of Alopecia Treatment industry.

Global Alopecia Treatment Market Professional Survey 2019 by Manufacturers, Regions, Countries, Types and Applications, Forecast to 2024

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market

Covid-19 Impact on Alopecia Treatment Market, Global Research Reports 2020-2021

This report provides a complete quantitative data and qualitative analysis on the global market for Alopecia Treatment. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.

Prior to COVID-19, the global market for Alopecia Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Alopecia Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.

This report covers market size and forecasts of Alopecia Treatment, including the following market information:

Global Alopecia Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)

Global Alopecia Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)

Global Alopecia Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)

Global Alopecia Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market players

Major competitors identified in this market include Teva Pharmaceutical Industries, Merck, Johnson&Johnson, Reddy’s Laboratories, Cipla, Cellmid, Himalaya Drug, Taisho Pharmaceutical Holdings, etc.

Based on the Region:

Asia-Pacific (China, Japan, South Korea, India and ASEAN)

North America (US and Canada)

Europe (Germany, France, UK and Italy)

Rest of World (Latin America, Middle East & Africa)

Based on the Type:

Topical Drugs

Oral Drugs

Injectable

Hair Transplant Services

Other

Based on the Application:

Hospitals

Dermatology And Trichology Clinics

Home Care Settings

Other

Covid-19 Impact on Alopecia Treatment Market, Global Research Reports 2020-2021

Source

Previous Posts

Alopecia Treatment Market Insights

Alopecia Treatment Market

Alopecia Treatment Market Poised to Grow at a CAGR of XX% Between 2020 – 2030

Alopecia Treatment Market research report is a professional and an in-depth study available on the market size, share, growth, trends, in addition to industry evaluation. Alopecia Treatment Market report provides a thorough analysis and competitive analysis by region and added main information like a manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, revenue, historical and futuristic cost, demand and supply data.

Moreover, the study presents a feasible estimate of the current market scenario, including the Alopecia Treatment market size with regards to value and volume. This extensive report is a gathering of significant data related to the competitive scenario of the industry. Further, it encompasses data with regards to various regions that have successfully established its position in the Alopecia Treatment industry.

Key players profile in the report include (Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Histogen, Inc.
  • Aclaris Therapeutics, Inc.
  • Concert Pharmaceuticals, Inc.
  • HCell Inc.
  • GlaxoSmithKline Plc.
  • Daiichi Sankyo, Inc.
  • Cipla Limited.

Segmentation of the report:

By Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, Alopecia Totalis)

By Drug Type (Vasodilators, 5-Alpha Reductase Inhibitors, Corticosteroids, Immunosuppressants, and Others) By Gender (Male, and Female)

 

By Route of Administration (Oral, Topical, and Injectable)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

By Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa)

 

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Scope of Market:

  • The Alopecia Treatment market report helps in making informed business decisions by having complete insights and by in-depth analysis of market segments
  • It provides a sharp analysis of varying competition dynamics and keeps you ahead of competitors 
  • Analysis of the numerous growth opportunities in the Alopecia Treatment Industry for stakeholders and to offer details of the competitive landscape for noteworthy players
  • Key points related to the focus on the Alopecia Treatment market like the product definition, range of application, revenue and demand and supply statistics.
  • Growth of the Global Alopecia Treatment Market industry across different geographies such as North America, Europe, Asia-Pacific, South America, and Middle East & Africa
  • Competitive Analysis of the top competitors operating in the market along with analyzing the latest trends and business strategies used by various companies.

Alopecia Treatment Market Poised to Grow at a CAGR of XX% Between 2020 – 2030

Source

Previous Posts